Stoking Functional Copies of Genes to Compensate for Mutated Ones

RARECast - A podcast by RARECast - Thursdays

Categories:

Ed Kaye, CEO of Stoke Therapeutics, discusses the company’s platform technology to address diseases in which people have one functional copy of a gene and one mutated copy, how it works, and its lead program in Dravet syndrome.